Program
Clomiphene
Also written as “Antioxidants + Clomiphene Citrate”, “Clomiphene Citrate 50 mg” and “Clomiphene Citrate 100 mg”.
Its studies are mostly in Oligospermia · Anovulation · Infertility, led by 3 companies.
Drug pageClomiphene: every studyAll 79 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hamad Medicalits history only | 11 open or running | phase 4since Sep 29, 2026 | Sep 29, 2026 | Oct 15, 2027phase 4 · NCT07862725 |
| Merck KGaA, Darmstadt, Germanyits history only | 10 open or running | phase 2since Sep 13, 2005 | Sep 13, 2005 | none ahead |
| Midwest Fertility Specialists | 10 open or running | no phasesince Oct 1, 2014 | Oct 1, 2014 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Midwest Fertility Specialists only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 1, 2014First study: no phase study in InfertilityFirst studyNCT02294773 · 13 enrolled · United States
TargetBeta
“Estrogen receptor alpha modulator”ChEMBL 37, by rule
Other programs on ESR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Ethinyl Estradiolrule | Johnson & Johnson | phase 4 | 70 |
| Estradiolrule | Novo Nordisk | phase 4 | 69 |
| Fulvestrantrule | AstraZeneca | phase 4 | 30 |
| Tamoxifenrule | AstraZeneca | phase 4 | 21 |
| vepdegestrantrule | Pfizer | phase 3 | 20 |
| camizestrantrule | AstraZeneca | phase 3 | 18 |
| giredestrant | Hoffmann-La Roche | phase 3 | 17 |
| HRS-8080 | Jiangsu HengRui Medicine | phase 3 | 13 |
| elacestrantrule | Menarini Group | phase 3 | 12 |
| Imlunestrantrule | Eli Lilly | phase 3 | 12 |
| taragarestrantrule | InventisBio | phase 3 | 5 |
| SIM0270rule | Simcere Pharmaceutical Group | phase 3 | 5 |
Studies
The one study Midwest Fertility Specialists leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02294773Infertility · United States | – | Completed | Sep 2015 | 13 |
How it is read
Names in the registry
- “Antioxidants + Clomiphene Citrate”, 1 entry
- “Clomiphene Citrate 50 mg”, 1 entry
- “Clomiphene Citrate 100 mg”, 1 entry
- “Clomiphene”, 1 entry
Conditions, from the studies’ own filings
- Oligospermia, 1 study
- Anovulation, 1 study
- Infertility, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.